µÎ°³ÀúÇÐ
- ÀúÀÚ(±Û)µÎ°³Àú¿Ü°úÇÐȸ
- ÃâÆÇ»ç±ºÀÚÃâÆÇ»ç
- ¹ßÇàÀÏ2023³â 11¿ù 22ÀÏ
ȯÀÚ ¾ÈÀüÀ» ¿ì¼±À¸·Î »ý°¢ÇÏ´Â ³úÁ¾¾ç ¼ö¼ú ±ÇÀ§ÀÚ
| Á¦ ¸ñ | µÎ°³Àú¿Ü°úÇÐ |
|---|---|
| ÃâÆÇ»ç | ±ºÀÚÃâÆÇ»ç |
| ¹ßÇàÀÏ | 2012³â 11¿ù 10ÀÏ |
| Á¦ ¸ñ | ½Å°æ¿Ü°úÇÐ |
|---|---|
| ÃâÆÇ»ç | ´ëÇѽŰæ¿Ü°úÇÐȸ |
| ¹ßÇàÀÏ | 2012³â 10¿ù 18ÀÏ |
| Á¦ ¸ñ | Atlas of Practical Neuroendoscopy |
|---|---|
| ÃâÆÇ»ç | ¿¬¼¼´ëÇб³ ´ëÇÐÃâÆÇ¹®È¿ø |
| ¹ßÇàÀÏ | 2001³â 04¿ù 12ÀÏ |
| Á¦ ¸ñ | Influence of Concurrent and Adjuvant Temozolomide on Health-Related Quality of Life of Patients with Grade III Gliomas |
|---|---|
| ¹ßÇ¥³âµµ | 2022 |
| ¹ßÇ¥Áö | Cancer Research and Treatment |
| Á¦ ¸ñ | Concurrent and Adjuvant Temozolomide for Newly Diagnosed Grade III Gliomas without 1p/19q Co-deletion: A Randomized, Open-Label, Phase 2 Study (KNOG-1101 Study) |
|---|---|
| ¹ßÇ¥³âµµ | 2020 |
| ¹ßÇ¥Áö | Cancer Research and Treatment |
| Á¦ ¸ñ | Dramatic unilateral decrease in uptake via the dopamine transporter: Imaging in a patient with hemiparkinsonism following the lacunar stroke in substantia nigra |
|---|---|
| ¹ßÇ¥³âµµ | 2019 |
| ¹ßÇ¥Áö | Neurology Asia |
| Á¦ ¸ñ | Impact of adjuvant treatments on survival in Korean patients with WHO grade II gliomas: KNOG 15-02 and KROG 16-04 intergroup study |
|---|---|
| ¹ßÇ¥³âµµ | 2018 |
| ¹ßÇ¥Áö | Journal of Neuro-oncology |
| Á¦ ¸ñ | Multi-institutional study of treatment patterns in Korean patients with WHO grade II gliomas: KNOG 15-02 and KROG 16-04 intergroup study |
|---|---|
| ¹ßÇ¥³âµµ | 2018 |
| ¹ßÇ¥Áö | Journal of Neuro-oncology |
| Á¦ ¸ñ | Rapidly Growing Anaplastic Ganglioglioma Mimicking Brain Metastasis in a Middle-Aged Woman: A Case Report |
|---|---|
| ¹ßÇ¥³âµµ | 2018 |
| ¹ßÇ¥Áö | ´ëÇÑ¿µ»óÀÇÇÐȸÁö |
ȯÀÚ°¡ '¾ÈÀü'ÇϰÔ, ±×¸®°í ȯÀÚÀÇ »óÅ¿¡ ¸Â´Â '¸ÂÃãÇü Ä¡·á'¸¦ °¡Àå Áß¿äÇÏ°Ô »ý°¢ÇÕ´Ï´Ù.
³ú¼ö¼ú¿¡ ´ëÇÑ µÎ·Á¿òÀ¸·Î Ä¡·á¸¦ ÇÇÇÏ´Â ºÐµéµµ ¸¹½À´Ï´Ù. ÇÏÁö¸¸ ±×·± ȯÀÚÀÇ ¸¶À½À» ¾Ë±â¿¡ Ç×»ó ȯÀÚ°¡ ¾ÈÀüÇÏ°Ô ±×¸®°í ȯÀÚÀÇ »óÅ¿¡ ¸Â´Â Ä¡·á¹ýÀ» Ç×»ó °í¹ÎÇÕ´Ï´Ù. ³ú¼ö¼úÀº ¹«¼·Áö ¾Ê½À´Ï´Ù!

°¡Å縯°üµ¿´ëÇб³ ±¹Á¦¼º¸ðº´¿øÀº °¡Å縯±³È¸ Á¤½ÅÀÎ ±×¸®½ºµµÀÇ ÀǼú·Î ÀηùÀÇ ¾ÆÇ ¸ö°ú ¸¶À½À» Ä¡À¯ÇÑ´Ù´Â ¹Ì¼Ç ¾Æ·¡ ¼³¸³µÆ´Ù. ÀÎõ±¹Á¦°øÇ×°ú °¡Àå °¡±î¿î ´ëÇѹα¹ÀÇ °ü¹® º´¿øÀÌÀÚ, ÀÎõ ¼±¸¿Í ¿µÁ¾µµ, °È, ±èÆ÷ Áö¿ª ÃÖÃÊ-À¯ÀÏÀÇ ´ëÇк´¿øÀÌ´Ù. ½ÉÀåÇ÷°ü¼¾ÅÍ, ·Îº¿¼ö¼ú¼¾ÅÍ, °ÅÁ¡Áö¿ª ÀÀ±ÞÀÇ·á¼¾ÅÍ, ±¹Á¦Áø·á¼¾ÅÍ µî Àü¹® ¼¾Å͸¦ ¿î¿µÇϸç ÁßÁõÀÀ±ÞÁúȯ Ä¡·á¿¡ Èû¾²°í ÀÖ´Ù.
ÀÎõ±¤¿ª½Ã ¼±¸ ½É°î·Î 100¹ø±æ 25